(*) EU CE Mark Date: 2022. 05.02
(*) JP Approval Date: 2021. 03.24.
(*) USA Approval Date: 2020. 06.11
>Cytolytic MAb
Company
Company Licensee JP
Generic Name: inebilizumab-cdon
NMOSD: NeuroMyelitis Optica Spectru
Patent>Assignee; Claims; No.; Etc
Patent>UpDate: 2022. 07.12
RTM
RTM Web-Site